Argus Clinical Ltd 10732437 false 2024-05-01 2025-04-30 2025-04-30 The principal activity of the company is Mangement Consultancy. The company ceased trading 30.4.25 and is in the process of being closed. Digita Accounts Production Advanced 6.30.9574.0 true 10732437 2024-05-01 2025-04-30 10732437 2025-04-30 10732437 bus:OrdinaryShareClass1 2025-04-30 10732437 core:CurrentFinancialInstruments 2025-04-30 10732437 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 10732437 bus:SmallEntities 2024-05-01 2025-04-30 10732437 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 10732437 bus:FilletedAccounts 2024-05-01 2025-04-30 10732437 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 10732437 bus:RegisteredOffice 2024-05-01 2025-04-30 10732437 bus:Director1 2024-05-01 2025-04-30 10732437 bus:OrdinaryShareClass1 2024-05-01 2025-04-30 10732437 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 10732437 bus:Agent1 2024-05-01 2025-04-30 10732437 countries:AllCountries 2024-05-01 2025-04-30 10732437 2023-05-01 2024-04-30 10732437 2024-04-30 10732437 bus:OrdinaryShareClass1 2024-04-30 10732437 core:CurrentFinancialInstruments 2024-04-30 10732437 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10732437

Argus Clinical Ltd
Unaudited Filleted Financial Statements
for the Year Ended 30 April 2025

Argus Clinical Ltd

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 4

Argus Clinical Ltd

Company Information

Director | Miss SA Hughes

Registered office | Blossom End Heads Lane Inkpen Hungerford Berks RG17 9QS

Accountants | EJBC Chartered Accountants 2 Toomers Wharf Canal Walk Newbury Berkshire RG14 1DY

Argus Clinical Ltd

(Registration number: 10732437)
Balance Sheet as at 30 April 2025

| Note | 2025 £ | 2024 £
Current assets |  |  |
Debtors |  | 412 | -
Cash at bank and in hand |  | 64,108 | 64,090
|  | 64,520 | 64,090
Creditors: Amounts falling due within one year |  | (64,420) | (1,857)
Net assets |  | 100 | 62,233
Capital and reserves |  |  |
Called up share capital | 3 | 100 | 100
Retained earnings |  | - | 62,133
Shareholders' funds |  | 100 | 62,233

For the financial year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the director on 24 October 2025

......................................... Miss SA Hughes Director

Argus Clinical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

1 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Argus Clinical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

2 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

3 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Odinary shares of £1 each | 100 | 100 | 100 | 100